4.904

0.20% -0.006

Sage Therapeutics Inc (SAGE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SAGE Giù? Forum Previsione

Precedente Chiudi:

$4.91

Aprire:

$5.02

Volume 24 ore:

907.18K

Relative Volume:

1.31

Capitalizzazione di mercato:

$304.64M

Reddito:

$91.06M

Utile/perdita netta:

$-503.14M

Rapporto P/E:

-0.4944

EPS:

-9.92

Flusso di cassa netto:

$-424.74M

1 W Prestazione:

-8.74%

1M Prestazione:

-37.09%

6M Prestazione:

-59.33%

1 anno Prestazione:

-74.66%

Intervallo 1D:

$4.80

$5.19

Intervallo di 1 settimana:

$4.62

$5.44

Portata 52W:

$4.62

$28.26

Sage Therapeutics Inc Stock (SAGE) Company Profile

Nome

Sage Therapeutics Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

617-299-8380

Indirizzo

55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA

Dipendente

487

Cinguettio

@SageBiotech

Prossima data di guadagno

2024-10-29

Ultimi documenti SEC

SAGE's Discussions on Twitter

Confronta SAGE con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SAGE	4.90	304.64M	91.06M	-503.14M	-424.74M	-9.92
VRTX	450.37	115.43B	10.63B	-479.80M	-1.35B	13.33
REGN	747.10	82.04B	13.85B	4.65B	3.32B	35.06
ARGX	591.88	35.30B	1.86B	-40.29M	-1.28B	-4.16
ALNY	246.29	32.04B	2.09B	-332.26M	16.06M	-4.14
BNTX	107.52	24.89B	3.30B	-501.07M	1.03B	11.54

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-12-12	Iniziato	Deutsche Bank	Hold
2023-08-08	Downgrade	Canaccord Genuity	Buy → Hold
2023-08-08	Downgrade	Goldman	Buy → Neutral
2023-08-08	Downgrade	Needham	Buy → Hold
2023-08-07	Downgrade	BofA Securities	Buy → Neutral
2023-08-07	Downgrade	Oppenheimer	Outperform → Perform
2023-08-07	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2023-08-07	Downgrade	Stifel	Buy → Hold
2023-08-07	Downgrade	Wedbush	Outperform → Neutral
2023-07-27	Iniziato	Scotiabank	Sector Outperform
2023-03-13	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-01-03	Downgrade	Guggenheim	Buy → Neutral
2022-11-01	Iniziato	Loop Capital	Hold
2022-03-31	Iniziato	Berenberg	Hold
2021-11-02	Aggiornamento	Guggenheim	Neutral → Buy
2021-10-19	Ripresa	Morgan Stanley	Equal-Weight
2021-10-07	Downgrade	Jefferies	Buy → Hold
2021-09-23	Iniziato	Needham	Buy
2021-06-16	Downgrade	Citigroup	Buy → Neutral
2021-04-07	Iniziato	Piper Sandler	Overweight
2021-02-26	Downgrade	Mizuho	Buy → Neutral
2021-02-25	Reiterato	H.C. Wainwright	Neutral
2021-02-02	Ripresa	Raymond James	Mkt Perform
2021-01-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
2021-01-04	Aggiornamento	Guggenheim	Neutral → Buy
2021-01-04	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2020-12-04	Aggiornamento	Mizuho	Neutral → Buy
2020-12-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-11-16	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-11-06	Reiterato	H.C. Wainwright	Neutral
2020-09-11	Aggiornamento	Wedbush	Neutral → Outperform
2020-08-10	Aggiornamento	Raymond James	Mkt Perform → Outperform
2020-05-08	Downgrade	Wedbush	Outperform → Neutral
2020-04-08	Downgrade	Guggenheim	Buy → Neutral
2020-03-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2020-03-06	Iniziato	Citigroup	Buy
2020-02-28	Reiterato	H.C. Wainwright	Neutral
2020-02-06	Iniziato	Mizuho	Neutral
2019-12-06	Reiterato	RBC Capital Mkts	Outperform
2019-12-05	Reiterato	Guggenheim	Buy
2019-12-05	Downgrade	SunTrust	Buy → Hold
2019-10-30	Iniziato	H.C. Wainwright	Neutral
2019-05-23	Iniziato	Wedbush	Outperform
2019-04-25	Iniziato	Jefferies	Buy
2018-12-14	Iniziato	Wolfe Research	Outperform
2018-10-11	Iniziato	Oppenheimer	Outperform

Mostra tutto

Sage Therapeutics Inc Borsa (SAGE) Ultime notizie

12:13 PM

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More - Yahoo Finance

12:13 PM

11:00 AM

Sage raised to sector perform by RBC in wake of drug failure - MSN

11:00 AM

07:41 AM

Sage scraps dalzanemdor after disappointing trial results - The Pharma Letter

07:41 AM

01:00 AM

Sage Therapeutics' Experimental Drug for Huntington's Disease Fails Mid-Stage Trial - Medical Dialogues

01:00 AM

12:43 PM

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder - AOL

12:43 PM

Nov 20, 2024

Sage’s Pipeline Prospects Narrow Further As Dalzanemdor Fails In Huntington’s - Citeline News & Insights

Nov 20, 2024

Third trial failure is end-of-the-road for Sage's neurological drug - The Business Journals

Nov 20, 2024

Sage to abandon development of neurological disorder drug after multiple failures - Reuters

Nov 20, 2024

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics - Benzinga

Nov 20, 2024

Sage Therapeutics (NASDAQ:SAGE) Earns Hold Rating from Needham & Company LLC - MarketBeat

Nov 20, 2024

Sage stock slips as Huntington’s Disease trial fails (SAGE:NASDAQ) - Seeking Alpha

Nov 20, 2024

Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again - MarketWatch

Nov 20, 2024

Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study - XM

Nov 20, 2024

Sage Therapeutics’ stock slides after trial of Huntington’s Disease treatment fails and company says it will end it - MarketWatch

Nov 20, 2024

Sage Therapeutics' rare disease drug fails mid-stage study - XM

Nov 20, 2024

Sage Therapeutics Ends Huntington's Drug Development After Failed Phase 2 Trial | SAGE Stock News - StockTitan

Nov 20, 2024

Sage Therapeutics' stock falls after therapy fails for a third time - MarketWatch

Nov 20, 2024

Nov 19, 2024

CNS Drug Development: Same As It Ever Was (SAGE) - Seeking Alpha

Nov 19, 2024

Nov 18, 2024

Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace

Nov 18, 2024

Nov 16, 2024

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com

Nov 16, 2024

Nov 15, 2024

BB Biotech AG's Strategic Acquisition of Sage Therapeutics Shares - GuruFocus.com

Nov 15, 2024

Nov 13, 2024

FMR LLC Adjusts Stake in Sage Therapeutics Inc - GuruFocus.com

Nov 13, 2024

Nov 09, 2024

Easterly Investment Partners LLC Sells 91,500 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat

Nov 09, 2024

Nov 05, 2024

Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com

Nov 05, 2024

Vanguard Group Inc's Recent Transaction in Sage Therapeutics Inc - GuruFocus.com

Nov 05, 2024

Nov 04, 2024

Objective long/short (SAGE) Report - Stock Traders Daily

Nov 04, 2024

Nov 02, 2024

Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) sh - GuruFocus.com

Nov 02, 2024

Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seekin - GuruFocus.com

Nov 02, 2024

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com

Nov 02, 2024

Pinnacle Associates Ltd. Has $1.22 Million Stock Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat

Nov 02, 2024

Sage Therapeutics Inc Sued for Securities Law ViolationsConta - GuruFocus.com

Nov 02, 2024

Nov 01, 2024

Sage Therapeutics Reports Q3 Growth and Strategic Focus - TipRanks

Nov 01, 2024

Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso - Citeline News & Insights

Nov 01, 2024

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - GuruFocus.com

Nov 01, 2024

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN

Nov 01, 2024

Sage Therapeutics CFO Kimi Iguchi resigns from position - XM

Nov 01, 2024

SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures - TipRanks

Nov 01, 2024

Cambridge biotech's layoffs will cut dozens of Mass. employees - The Business Journals

Nov 01, 2024

HC Wainwright Expects Weaker Earnings for Sage Therapeutics - MarketBeat

Nov 01, 2024

Oct 31, 2024

What is HC Wainwright's Estimate for SAGE FY2028 Earnings? - MarketBeat

Oct 31, 2024

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Call Transcript - Insider Monkey

Oct 31, 2024

Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler - Yahoo Finance

Oct 31, 2024

Oct 30, 2024